IMVT

Immunovant Inc

Add to Watchlist

Advanced Chart

16.950

-1.37(-7.478%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

17.310

Open

16.320

VWAP

16.86

Vol

4.51M

Mkt Cap

2.90B

Low

15.310

Amount

76.08M

EV/EBITDA(TTM)

Total Shares

146.05M

2.42B

EV/OCF(TTM)

P/S(TTM)

Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q3

FY2026Q2

FY2026Q1

-0.726

-4.53%

-0.710

-4.05%

-0.686

+14.26%

Estimates Revision

Stock Price

Go Up

+9.92%

In Past 3 Month

10 Analyst Rating

145.84% Upside

Wall Street analysts forecast IMVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMVT is 41.67 USD with a low forecast of 18.00 USD and a high forecast of 58.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

2 Hold

0 Sell

Strong Buy

145.84% Upside

Current: 16.950

Low

18.00

Averages

41.67

High

58.00

145.84% Upside

Current: 16.950

Low

18.00

Averages

41.67

High

58.00

Goldman Sachs

Neutral

maintain

$18

2025-07-10

Reason

Goldman Sachs

Price Target

$18

2025-07-10

maintain

Neutral

Reason

Goldman Sachs resumed coverage of Immunovant with a Neutral rating and $18 price target. The firm sees limited downside but also a challenging regulatory backdrop for the company.

H.C. Wainwright

Buy

downgrade

$51 -> $35

2025-05-30

Reason

H.C. Wainwright

Price Target

$51 -> $35

2025-05-30

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Immunovant to $35 from $51 and keeps a Buy rating on the shares. The target cut reflects the company's data readouts in 2027, with an expected potential launch in 2028.

UBS

Colin Bristow

Strong Buy

Hold

Downgrades

$38 → $17

2025-04-22

Reason

UBS

Colin Bristow

Price Target

$38 → $17

2025-04-22

Downgrades

Strong Buy

Hold

Reason

UBS downgraded Immunovant to Neutral from Buy with a price target of $17, down from $38.

B of A Securities

Jason Gerberry

Strong Buy

Maintains

$38 → $33

2025-03-20

Reason

B of A Securities

Jason Gerberry

Price Target

$38 → $33

2025-03-20

Maintains

Strong Buy

Reason

Guggenheim

Yatin Suneja

Strong Buy

Reiterates

n/a

2025-03-20

Reason

Guggenheim

Yatin Suneja

Price Target

n/a

2025-03-20

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Douglas Tsao

Strong Buy

Reiterates

$51

2025-03-19

Reason

HC Wainwright & Co.

Douglas Tsao

Price Target

$51

2025-03-19

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Immunovant Inc (IMVT.O) is -6.43, compared to its 5-year average forward P/E of -11.89. For a more detailed relative valuation and DCF analysis to assess Immunovant Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-11.89

Current PE

-6.43

Overvalued PE

-2.86

Undervalued PE

-20.91

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-9.72

Current EV/EBITDA

-5.07

Overvalued EV/EBITDA

-0.93

Undervalued EV/EBITDA

-18.51

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

12.00

Current PS

329.87

Overvalued PS

68.36

Undervalued PS

-44.36

Financials

Annual

Quarterly

FY2025Q4

YoY :

+40.73%

-113.83M

Operating Profit

FY2025Q4

YoY :

+41.33%

-106.45M

Net Income after Tax

FY2025Q4

YoY :

+23.08%

-0.64

EPS - Diluted

FY2025Q4

YoY :

+85.20%

-110.84M

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

140.4K

USD

3-6

Months

1.1M

USD

6-9

Months

1.0M

USD

0-12

Months

1.3M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

336.9M

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 133.13% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

373.9K

Volume

6-9

Months

2.0M

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

8.3M

Volume

Months

6-9

3.5M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

140.4K

USD

3-6

Months

1.1M

USD

6-9

Months

1.0M

USD

0-12

Months

1.3M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

336.9M

USD

Months

0-12

0.0

USD

Months

IMVT News & Events

Events Timeline

2025-07-25 (ET)

2025-07-25

07:49:40

Immunovant 3M share Block Trade priced at $17.85

2025-07-24 (ET)

2025-07-24

17:18:49

Immunovant 3M share Block Trade; price range $17.85-$18.00

2025-05-29 (ET)

2025-05-29

07:08:08

Immunovant sees cash runway through GD readout expected in 2027

News

8.0

07-25NASDAQ.COM

Noteworthy Friday Option Activity: IMVT, MOD, PCG

4.0

06-02TipRanks

3 Best Stocks to Buy Now, 6/2/2025, According to Top Analysts

7.0

05-29PRnewswire

IMVT INVESTIGATION ALERT: Investigation Launched into Private Placement Transaction by Immunovant, Inc. and Attorneys Encourage Investors to Contact Law Firm